June 11, 2010
Targeting Diseases using Epigenetic Approaches
May 20, 2010
Strategic Alliance, International Stem Cell Corporation (OTCBB: ISCO) and The Automation Partnership
May 19, 2010
Positive Data on Small Molecule Telomerase Activator in Model of Idiopathic Pulmonary Fibrosis (GERN)
May 9, 2010
Q1/10 Results, Advanced Cell Technology, Inc. (OTCBB ACTC.OB)
May 2, 2010
Stem Cell Breakthrough for Growth of New Arteries
April 30, 2010
Ethics, Transparency and Integrity
January 12, 2010
Cash, Partners, Advanced Trials; Osiris Therapeutics
January 11, 2010
The Big Week for Investor Visibility, JP Morgan
December 14, 2009
A Therapeutic Advantage? NeoStem (AMEX:NBS)
November 6, 2009
Updating Q3/09, Athersys (NASDAQ: ATHX)
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.